恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

未开盘 05-19 16:08:20

61.500

-1.700

-2.69%

最高63.750	最低61.300	成交量359.29万
今开63.400	昨收63.200	日振幅3.88%
总市值4,082亿	流通市值158.67亿	总股本66.37亿
成交额2.23亿	换手率1.39%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":61.5,"timestamp":1779178100005,"preClose":63.2,"halted":0,"volume":3592938,"delay":0,"changeRate":-0.026898734177215233,"floatShares":258000000,"shares":6637000000,"eps":1.355936616353482,"marketStatus":"未开盘","change":-1.7,"latestTime":"05-19 16:08:20","open":63.4,"high":63.75,"low":61.3,"amount":222561768,"amplitude":0.038766,"askPrice":61.5,"askSize":35800,"bidPrice":61.45,"bidSize":1400,"shortable":3,"etf":0,"ttmEps":1.4027256224082967,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":63.2,"dividendRate":0.003752,"openAndCloseTimeList":[[1779154200000,1779163200000],[1779166800000,1779177600000]],"volumeRatio":0.477134,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":51.59,"timestamp":1779174000000,"preClose":52.43,"halted":0,"volume":69909400,"delay":0,"premium":"+3.74"}},"requestUrl":"/m/hq/s/01276","defaultTab":"news","newsList":[{"id":"2636837763","title":"恒瑞医药(01276)：ω-3 甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）获得药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636837763","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636837763?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:18","pubTimestamp":1779185930,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司 ω-3 甘油三酯(2%)中/长链脂肪乳/氨基酸/葡萄糖(30%)注射液上市。截至目前，ω-3 甘油三酯(2%)中/长链脂肪乳/氨基酸/葡萄糖(30%)注射液相关项目累计研发投入约 8,390 万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443505.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","600276","LU1997245094.SGD","LU2289578879.USD","LU2097828557.USD","LU1146622755.USD","LU1655091616.SGD","LU2580892862.HKD","LU0405327494.USD","01276","LU1064130708.USD","LU1969619763.USD","LU1781817850.SGD","BK0196","LU2097828805.USD","LU1023057109.AUD","LU2097828714.EUR","BK0028","LU0405327148.USD","LU1997244956.HKD","LU0359201885.HKD","BK0188","LU1820825898.SGD","LU2580892789.USD","LU2328871848.SGD","BK0012","BK1191","LU1580142542.USD","LU2148510915.USD","BK0060","BK0239","LU2495084118.USD","LU2543165471.USD","LU1328615791.USD","LU2097828631.EUR","LU2097828474.EUR","LU0359201612.USD","LU1064131003.USD","LU2488822045.USD","LU1255011170.USD","BK0183","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636563834","title":"恒瑞医药子公司复方营养注射液获批上市 累计研发投入约8390万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636563834","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636563834?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:12","pubTimestamp":1779181920,"startTime":"0","endTime":"0","summary":"5月19日，恒瑞医药（600276/01276）发布公告，公司子公司福建盛迪医药有限公司收到国家药品监督管理局的通知，批准公司ω-3甘油三酯（2%）中/长链脂肪乳/氨基酸（16）/葡萄糖（30%）注射液上市。该药品为处方药，注册分类为化学药品3类，适用于当口服或肠内营养无法进行、不足或有禁忌的中重度分解代谢成人患者。截至目前，相关项目累计研发投入约为8390万元（未经审计）。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193742055768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU0359201885.HKD","LU1655091616.SGD","LU2097828805.USD","LU1969619763.USD","LU1146622755.USD","LU1255011170.USD","LU1820825898.SGD","LU2580892862.HKD","LU2097828631.EUR","BK0196","LU2580892789.USD","LU2289578879.USD","BK0028","LU1781817850.SGD","BK0012","BK0239","LU1580142542.USD","LU1997245177.USD","LU0405327494.USD","LU1328615791.USD","BK0188","LU2495084118.USD","LU2328871848.SGD","LU1023057109.AUD","LU2488822045.USD","BK0060","LU0359201612.USD","600276","LU1997245094.SGD","LU2148510915.USD","LU0405327148.USD","BK0183","LU1064130708.USD","BK1191","LU1997244956.HKD","LU2097828474.EUR","IPOS","LU2543165471.USD","01276","LU0359202008.SGD","LU2097828557.USD","LU2097828714.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636078106","title":"Schroders PLC增持恒瑞医药(01276)66.3万股 每股作价约68.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2636078106","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636078106?lang=zh_cn&edition=full","pubTime":"2026-05-18 19:38","pubTimestamp":1779104328,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，5月12日，Schroders PLC增持恒瑞医药(01276)66.3万股，每股作价68.7041港元，总金额约为4555.08万港元。增持后最新持股数目为1317.12万股，持股比例为5.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1443064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU1655091616.SGD","LU2097828474.EUR","BK0060","LU1997244956.HKD","LU1580142542.USD","LU2097828714.EUR","LU1781817850.SGD","600276","LU0359201612.USD","EWH","LU1023057109.AUD","BK0196","LU1064131003.USD","LU2097828805.USD","LU2328871848.SGD","LU1997245177.USD","LU1969619763.USD","LU2488822045.USD","LU2495084118.USD","LU2580892862.HKD","BK0012","LU1997245094.SGD","LU0405327148.USD","LU1328615791.USD","LU0359202008.SGD","LU1146622755.USD","LU1255011170.USD","LU0359201885.HKD","LU2289578879.USD","LU2543165471.USD","01276","BK0188","LU0405327494.USD","BK1191","LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","LU2097828631.EUR","BK0239","BK0028","LU2097828557.USD","LU1820825898.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026816","title":"恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026816","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026816?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:48","pubTimestamp":1779094139,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：你好，贵司2025年新成立的生物制药事业部，请问在生物制药方面有什么新的进展？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740505938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740505938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2543165471.USD","LU1781817850.SGD","BK0183","BK0196","LU1580142542.USD","LU1328615791.USD","BK0188","LU0405327494.USD","BK1191","LU1146622755.USD","06978","LU2097828714.EUR","LU1023057109.AUD","LU0359202008.SGD","BK0028","LU2328871848.SGD","LU2495084118.USD","LU2580892862.HKD","LU0359201885.HKD","01276","LU2097828805.USD","LU1064130708.USD","BK1574","BK0060","LU1997245177.USD","LU1820825898.SGD","LU2488822045.USD","LU2097828631.EUR","IPOS","LU2097828474.EUR","LU1997244956.HKD","LU2289578879.USD","BK1161","LU1255011170.USD","LU2148510915.USD","159992","LU1655091616.SGD","LU2580892789.USD","LU2097828557.USD","BK0239","LU1969619763.USD","LU1997245094.SGD","LU0405327148.USD","BK0012","LU1064131003.USD","600276","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792414","title":"恒瑞医药：RSS0393乳胶获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792414","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792414?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:37","pubTimestamp":1778747820,"startTime":"0","endTime":"0","summary":"南财智讯5月14日电，恒瑞医药公告，RSS0393乳胶收到国家药品监督管理局《药物临床试验批准通知书》，同意本品开展用于特应性皮炎治疗的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737468040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1023057109.AUD","LU2148510915.USD","LU0405327494.USD","01276","LU2495084118.USD","600276","BK0012","LU1997245094.SGD","BK0196","LU0359201612.USD","LU0359201885.HKD","BK0188","LU1781817850.SGD","LU1255011170.USD","LU1146622755.USD","BK0183","LU2580892862.HKD","LU2580892789.USD","LU0359202008.SGD","LU1820825898.SGD","LU1064130708.USD","LU2328871848.SGD","LU1997245177.USD","LU2488822045.USD","BK0060","LU1064131003.USD","LU1328615791.USD","LU1969619763.USD","LU2097828474.EUR","LU2097828714.EUR","LU0405327148.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828557.USD","LU1655091616.SGD","BK1191","LU1580142542.USD","LU2543165471.USD","LU1997244956.HKD","LU2289578879.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635792748","title":"恒瑞医药(600276.SH)子公司SHR-3079注射液获批开展临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635792748","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635792748?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:36","pubTimestamp":1778747819,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局核准签发关于SHR-3079注射液《药物临床试验批准通知书》，将于近期开展临床试验。据悉，SHR-3079注射液是公司自主研发的创新型抗肿瘤药物，拟用于治疗B细胞非霍奇金淋巴瘤。经查询，目前国内外尚无同类药物获批上市。截至目前，SHR-3079注射液相关项目累计研发投入约为2340万元(未经审计)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0359202008.SGD","LU2097828474.EUR","LU2488822045.USD","LU2580892789.USD","LU1997244956.HKD","BK0012","LU2097828714.EUR","LU2495084118.USD","LU2097828631.EUR","LU1655091616.SGD","LU1820825898.SGD","LU1064131003.USD","BK0239","BK0183","BK1191","01276","LU1781817850.SGD","LU2289578879.USD","LU1997245094.SGD","LU1997245177.USD","LU1064130708.USD","LU1969619763.USD","LU0359201612.USD","LU1580142542.USD","LU2148510915.USD","BK0188","BK0060","LU2328871848.SGD","BK0196","LU1023057109.AUD","LU1146622755.USD","LU0405327494.USD","LU1328615791.USD","LU2097828805.USD","LU0359201885.HKD","600276","BK0028","LU1255011170.USD","LU2097828557.USD","LU2580892862.HKD","LU2543165471.USD","LU0405327148.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635794944","title":"智通AH统计|5月14日","url":"https://stock-news.laohu8.com/highlight/detail?id=2635794944","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635794944?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:15","pubTimestamp":1778746506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月14日收盘，东北电气、浙江世宝、弘业期货分列AH溢价率前三位，溢价率分别为575.00%、366.67%、313.94%；宁德时代、兆易创新、招商银行分列AH溢价率末三位，溢价率分别为-25.44%、-17.12%、-4.61%。其中大唐发电、南华期货股份、安德利果汁的偏离值位居前三，分别为128.05%、57.70%、54.74%；另外，龙旗科技、中国人寿、中国交通建设的偏离值位居后三，分别为-18.16%、-16.21%、-15.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","00042","00187","01033","09981","06166","03296","03750","03986","06127","00323","03328","02318","399300","03996","159982","00811","01276","PAImain","02628","02359","02899","01108","601318","01812","00991","EWH","03145","02338","00300","06826","01349","02218","03143","03678","LU0543330483.HKD","09611","IE00BYV24P56.USD","03968","01057","00553","02691","00568","PNGAY","82318","HPAD.SI","01800","LU0898667661.SGD","00981"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635320782","title":"携手推进肿瘤学、血液学及免疫学创新疗法 恒瑞医药与百时美施贵宝达成战略合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635320782","media":"经济参考网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635320782?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:20","pubTimestamp":1778664054,"startTime":"0","endTime":"0","summary":"5月12日，江苏恒瑞医药股份有限公司(简称“恒瑞医药”，600276.SH;01276.HK)与百时美施贵宝公司(简称“BMS”，NYSE：BMY)宣布达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学领域的早期创新项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735980065.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327494.USD","LU2495084118.USD","LU2242646821.SGD","LU2328871848.SGD","LU1093756168.USD","LU1571399168.USD","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU0985481810.HKD","LU1655091616.SGD","BK4007","LU1868837300.USD","LU1670710588.SGD","600276","LU0321505439.SGD","LU1670711040.USD","LU1820825898.SGD","LU2097828714.EUR","LU0359201612.USD","IE00B2B36J28.USD","IE00BFXG1179.USD","LU2097828805.USD","BK0183","LU0306807586.USD","LU1868836757.USD","BK0060","LU1023057109.AUD","BK0012","BMY","LU2242652126.USD","LU0882574055.USD","LU2125154778.USD","LU0225284248.USD","LU1997245177.USD","01276","LU0432979614.USD","BK4532","LU1868836591.USD","LU1670710661.SGD","LU1585245621.USD","IE0009355771.USD","LU0237698245.USD","LU0225771236.USD","LU2097828474.EUR","LU2097828557.USD","LU2543165471.USD","LU2580892862.HKD","LU0405327148.USD","LU1146622755.USD","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635040892","title":"恒瑞医药子公司获三项临床批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2635040892","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635040892?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:52","pubTimestamp":1778662320,"startTime":"0","endTime":"0","summary":"5月13日，恒瑞医药（600276/01276）发布公告，公司子公司苏州盛迪亚生物医药有限公司、上海盛迪医药有限公司近日收到国家药品监督管理局核准签发的关于SHR-3821注射液、阿得贝利单抗注射液、瑞拉芙普α注射液的《药物临床试验批准通知书》，将于近期开展临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735945731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0359202008.SGD","LU2580892789.USD","LU1820825898.SGD","LU2488822045.USD","LU2580892862.HKD","LU2097828805.USD","BK0012","LU1146622755.USD","LU2543165471.USD","LU2097828474.EUR","600276","LU1064131003.USD","LU1023057109.AUD","LU2495084118.USD","01276","BK0188","LU1655091616.SGD","LU2328871848.SGD","BK0183","LU2289578879.USD","LU2097828557.USD","LU1328615791.USD","BK1191","LU1064130708.USD","BK0028","LU2148510915.USD","LU1781817850.SGD","LU1997245177.USD","LU0359201885.HKD","LU2097828631.EUR","LU0405327494.USD","LU0359201612.USD","LU0405327148.USD","LU1580142542.USD","LU1969619763.USD","BK0239","BK0060","LU2097828714.EUR","LU1997244956.HKD","LU1255011170.USD","LU1997245094.SGD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635920479","title":"恒瑞医药：SHR-3821注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2635920479","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635920479?lang=zh_cn&edition=full","pubTime":"2026-05-13 16:47","pubTimestamp":1778662020,"startTime":"0","endTime":"0","summary":"南财智讯5月13日电，恒瑞医药公告，SHR-3821注射液收到国家药品监督管理局《药物临床试验批准通知书》，同意开展SHR-3821注射液联合其他抗肿瘤治疗在实体瘤患者中的安全性、耐受性和有效性的多中心、开放的Ib/II期临床研究。该药为公司自主研发的人源化抗体药物，拟用于治疗晚期实体瘤，可通过在肿瘤组织中特异性激活免疫细胞发挥抗肿瘤作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735943423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","600276","BK0060","LU2580892862.HKD","LU2097828805.USD","LU2097828714.EUR","LU1997244956.HKD","LU2328871848.SGD","LU1255011170.USD","LU2148510915.USD","LU0359202008.SGD","LU2488822045.USD","LU2543165471.USD","01276","LU2289578879.USD","LU1023057109.AUD","BK0196","LU1146622755.USD","LU2097828474.EUR","LU1580142542.USD","LU1655091616.SGD","LU0405327494.USD","LU0405327148.USD","LU2097828557.USD","LU0359201612.USD","BK0188","BK0028","LU1781817850.SGD","LU1064130708.USD","BK1191","LU2580892789.USD","BK0239","BK0012","LU2495084118.USD","LU1328615791.USD","BK0183","LU1997245177.USD","LU1064131003.USD","LU1820825898.SGD","LU1969619763.USD","LU2097828631.EUR","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635027823","title":"大摩：恒瑞医药(01276)与BMS缔152亿美元战略合作 加速全球化进程","url":"https://stock-news.laohu8.com/highlight/detail?id=2635027823","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635027823?lang=zh_cn&edition=full","pubTime":"2026-05-13 10:43","pubTimestamp":1778640196,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，摩根士丹利发布研报称，恒瑞医药(01276)与百时美施贵宝宣布一项涵盖13个临床前资产的全球战略合作，总交易价值达152亿美元(下同)。当中包括6亿美元预付款、2027至2028年合共3.5亿美元周年付款、最高143亿美元里程碑付款，以及分级销售里程权利金。该行维持恒瑞为中国医疗保健行业首选股，予“增持”评级，H股目标价92港元。该行认为，这项涵盖多种形式及资产模态的战略合作，进一步验证恒瑞医药的早期研发平台及提升的全球化能力。除了短期现金收益外，双向合作结构及共同开发与商业化选项，亦有望加快恒瑞的全球化步伐，并为其在中国市场不断扩展的免疫学产品组合带来商业协同效应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441038.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2580892789.USD","LU2148510915.USD","LU2097828557.USD","BK0028","LU1064131003.USD","LU1781817850.SGD","LU0359201885.HKD","LU1064130708.USD","BMS","LU1655091616.SGD","LU2097828805.USD","LU2289578879.USD","BK0183","BK0012","LU0405327148.USD","LU1146622755.USD","LU1255011170.USD","LU1328615791.USD","BK0196","LU1820825898.SGD","LU2097828714.EUR","BK0188","LU1997245094.SGD","LU2495084118.USD","LU1997245177.USD","BK0239","01276","LU1023057109.AUD","LU0359202008.SGD","LU2097828474.EUR","LU1997244956.HKD","LU1969619763.USD","BK1191","LU0359201612.USD","LU0405327494.USD","LU2328871848.SGD","LU1580142542.USD","LU2543165471.USD","LU2097828631.EUR","BK0060","600276","LU2580892862.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635221419","title":"恒瑞医药与BMS刷新合作纪录；默沙东与多家药企签署协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2635221419","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635221419?lang=zh_cn&edition=full","pubTime":"2026-05-13 08:02","pubTimestamp":1778630577,"startTime":"0","endTime":"0","summary":"政策动向国家药监局局长黄果会见新加坡卫生科学局局长蔡瑞文双方就创新医疗器械等议题深入交换意见国家药监局局长黄果5月11日在京会见了来访的新加坡卫生科学局局长蔡瑞文一行，并签署《中华人民共和国国家药品监督管理局与新加坡共和国卫生科学局监管合作谅解备忘录》。双方就细胞和基因治疗、创新医疗器械及人工智能产品监管等议题深入交换意见。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605133735150673.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605133735150673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","LU2360032135.SGD","LU1037948541.HKD","LU1989772840.SGD","BK0239","LU2097828557.USD","LU1116320737.USD","BK1191","LU1255011170.USD","LU0405327148.USD","LU0965508806.USD","LU1941712264.USD","SG9999001440.SGD","IE00BJJMRZ35.SGD","01276","LU0070302665.USD","BK4585","LU0432979614.USD","LU0861579265.USD","LU1066051498.USD","LU1064130708.USD","BK0012","LU1974910355.USD","LU1655091616.SGD","BK4007","LU0106261372.USD","LU0006306889.USD","BK0196","LU0203345920.USD","LU0859254822.USD","LU2361045086.USD","LU2543165471.USD","BK4550","LU1941712348.USD","SGXZ57979304.SGD","LU1934455863.HKD","LU1023057109.AUD","LU2097828805.USD","SG9999014575.USD","LU2580892789.USD","LU0477156953.USD","LU0203347892.USD","LU0234572021.USD","LU1057294990.SGD","LU1066053197.SGD","SG9999015341.SGD","IE00B4R5TH58.HKD","LU0266013472.USD","LU1983299246.USD","IE0002141913.USD","LU0980610538.SGD","LU1146622755.USD","LU2148510915.USD","LU2491049909.HKD","SG9999002224.SGD","SG9999002232.USD","LU0359202008.SGD","LU1069347547.HKD","LU1430594728.SGD","IE00BLSP4239.USD","LU0130102774.USD","LU1917777945.USD","SG9999014559.SGD","LU2361044865.SGD","LU2289578879.USD","BK4588","LU0965509283.SGD","LU2324357040.USD","IE00BLSP4452.SGD","LU1061106388.HKD","LU2488822045.USD","LU2106854487.HKD","LU1064131003.USD","BK4533","LU1969619763.USD","IE00BFTCPJ56.SGD","LU2361044949.HKD","LU2125154778.USD","LU1571399168.USD","LU0868494617.USD","LU1201861249.SGD","SG9999014542.SGD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU2089984988.USD","LU1093756325.SGD","LU1580142542.USD","LU1997245094.SGD","LU2491050071.SGD","LU2580892862.HKD","BK0183","LU0208291251.USD","LU1023059063.AUD","LU0405327494.USD","002022","LU1066051225.USD","LU0265550359.USD","LU0238689110.USD","LU0985320562.USD","LU1328615791.USD","SG9999001176.USD","LU1162221912.USD","LU1929549753.HKD","IE00B2B36J28.USD","IE00BN8TJ469.HKD","LU0648001328.SGD","BK0028","LU2468319806.SGD","LU1934455277.USD","SG9999014567.USD","BK4516","IE000M9KFDE8.USD","LU0098860793.USD","688506","LU1037948897.HKD","LU0868494708.USD","BK4559","LU0320765489.SGD","BK4534","LU0130517989.USD","LU1997244956.HKD","LU2112291526.USD","BK0060","IE0009355771.USD","LU1066051811.HKD","LU0359201612.USD","IE00BBT3K403.USD","MRK","BK0188","LU0942090050.USD","LU2097828714.EUR","SG9999001176.SGD","LU0211331839.USD","LU2097828474.EUR","LU1820825898.SGD","LU0265550946.USD","LU0320765646.SGD","LU1291159041.SGD","LU1093756168.USD","LU1997245177.USD","LU1781817850.SGD","LU2461242641.AUD","LU2491050154.USD","LU1585245621.USD","IE00BSNM7G36.USD","LU2328871848.SGD","LU2357627491.SGD","LU0965509101.SGD","301206","LU2023250843.SGD","LU1989772923.USD","SG9999013999.USD","LU1989771016.USD","LU0965509010.AUD","LU2097828631.EUR","LU0289739699.SGD","LU0359201885.HKD","LU1934455194.USD","LU2125154935.USD","LU1699723380.USD","LU1116320901.HKD","LU0058720904.USD","LU2023250504.SGD","LU2495084118.USD","SG9999015358.SGD","LU1035773651.USD","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634248737","title":"与跨国药企BMS双向授权，恒瑞医药拿下152亿美元BD大单，股价为何冲高回落？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634248737","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634248737?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:26","pubTimestamp":1778595960,"startTime":"0","endTime":"0","summary":"5月12日，A股医药板块迎来重磅消息。医药“老大哥”恒瑞医药（600276.SH；01276.HK）午后股价直线拉升，A股盘中一度触及涨停，港股一度涨超16%。不过，市场的亢奋情绪并未持续至收盘。随后股价震荡回落，截至收盘，恒瑞医药A股、港股涨幅均收窄至4.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734861793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU1328615791.USD","LU2328871848.SGD","LU2488822045.USD","LU1064131003.USD","LU1997245094.SGD","LU1969619763.USD","BK0183","LU1781817850.SGD","BMS","LU2543165471.USD","LU1064130708.USD","LU2097828557.USD","LU1146622755.USD","LU0359201612.USD","LU1997245177.USD","LU2097828805.USD","LU1997244956.HKD","LU2097828714.EUR","BK0060","LU1580142542.USD","LU0359201885.HKD","LU1820825898.SGD","BK1191","LU2097828631.EUR","LU1655091616.SGD","600276","LU2580892862.HKD","LU2148510915.USD","LU0359202008.SGD","LU1255011170.USD","01276","LU2097828474.EUR","BK0239","LU2289578879.USD","BK0188","BK0196","LU0405327148.USD","LU1023057109.AUD","LU2495084118.USD","LU2580892789.USD","BK0012","LU0405327494.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291117","title":"跨国巨头再现百亿美元级“天价”收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291117","media":"第一财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634291117?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:59","pubTimestamp":1778576361,"startTime":"0","endTime":"0","summary":"5月12日，恒瑞医药宣布，百时美施贵宝（BMS）与恒瑞医药达成授权协议，BMS将向恒瑞医药支付最高达9.5亿美元的相关付款，该协议的潜在总交易额可达约152亿美元。受该消息提振，恒瑞医药港股（1276.HK）股价一度上涨约15%。这项协议涵盖了恒瑞医药的13项创新项目，包括肿瘤学、血液学及免疫学。不过声明称，这些项目仍然处于早期研发阶段，尚未进入临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605123734535143.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605123734535143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0405327494.USD","LU2148510915.USD","LU1997245094.SGD","LU2289578879.USD","LU0359201612.USD","LU1328615791.USD","BK0012","LU0359202008.SGD","LU1064131003.USD","BMS","600276","BK0028","BK1191","LU1655091616.SGD","LU2097828474.EUR","LU2328871848.SGD","LU1255011170.USD","LU2488822045.USD","LU2097828714.EUR","LU2580892789.USD","BK0196","LU1781817850.SGD","BK0188","LU2097828557.USD","BK0183","LU0405327148.USD","LU1997245177.USD","LU1064130708.USD","BK0060","LU2495084118.USD","LU1580142542.USD","BK0239","01276","LU2097828631.EUR","LU2097828805.USD","LU0359201885.HKD","LU1969619763.USD","LU1023057109.AUD","LU1997244956.HKD","LU1146622755.USD","LU2543165471.USD","LU1820825898.SGD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634993172","title":"港股收盘(05.12) | 恒指收跌0.22% 石油、有色股逆市上扬 存储概念高位回落","url":"https://stock-news.laohu8.com/highlight/detail?id=2634993172","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634993172?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:31","pubTimestamp":1778574688,"startTime":"0","endTime":"0","summary":"截至收盘，恒生指数跌0.22%或58.93点，报26347.91点，全日成交额2626.47亿港元；恒生国企指数跌0.02%，报8882.37点；恒生科技指数跌0.7%，报5070.61点。蓝筹股表现快手-W逆市上涨。截至收盘，涨1.94%，报52.6港元，成交额82.89亿港元，贡献恒指4.81点。另一边，存储概念高位回落，韩国KOSPI指数今早一度跌超5%引发相关ETF集体跳水。Lumentum涨16.52%，创历史新高，康宁涨近11%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"18751d84c13ffc1c39803fa6ec3e0f06","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00358","BNO","FTXN","MHImain","XES","WTIU","DBC","KSTmain","OIH","01276","DRIP","XLE","159019","159876","MCHmain","DIG","IXC","OILK","OILU","LU2097828805.USD","BK1591","HSI","01024","ERX","GUSH","513600","LU0359202008.SGD","PXE","XOP","81024","LU0463099449.HKD","HHImain","PXJ","USE","BK1590","USL","VXUS","01766","USOI","LU2778985437.USD","OILT","HSImain","DBE","DRLL","07709","IEO","LU1794554557.SGD","02833","BK1594","VDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634016296","title":"智通AH统计|5月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2634016296","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634016296?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:27","pubTimestamp":1778574421,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止5月12日收盘，东北电气、浙江世宝、中石化油服分列AH溢价率前三位，溢价率分别为513.64%、344.81%、302.60%；宁德时代、兆易创新、药明康德分列AH溢价率末三位，溢价率分别为-19.99%、-16.60%、-4.65%。其中大唐发电、晨鸣纸业、南华期货股份的偏离值位居前三，分别为59.58%、36.27%、34.90%；另外，东北电气、长飞光纤光缆、中芯国际的偏离值位居后三，分别为-53.05%、-21.38%、-20.29%。　　前十大AH股溢价率排行。　　股票名称H股(港元)A股溢价率↓偏离值","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260512/32217919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688981","02465","82318","02628","06869","02238","PNGAY","02318","02701","00386","00588","01057","03143","03678","01800","601318","399300","01349","01033","HPAD.SI","03968","00042","00300","00981","03996","02899","02359","03908","00991","01766","06196","02338","159982","03986","00187","02691","01812","06185","EWH","01108","03145","00568","00553","PAImain","03328","06680","01276","03750","02218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634126909","title":"港股异动 | 恒瑞医药(01276)最高涨超16%  与百时美施贵宝达成战略合作协议 潜在总交易额达152亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634126909","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634126909?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:35","pubTimestamp":1778564111,"startTime":"0","endTime":"0","summary":"恒瑞医药(01276)午后急升，最高涨超16%，截至发稿，涨6.21%，报70.15港元，成交额10.14亿港元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260512/20260512133545_76516.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260512/20260512133545_76516.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1430594728.SGD","LU1580142542.USD","LU1969619763.USD","LU2242652126.USD","LU0868494617.USD","LU1323610961.USD","LU1868836757.USD","LU1146622755.USD","01276","LU1868836591.USD","BK0183","LU0405327494.USD","BK4585","LU1064131003.USD","LU1585245621.USD","LU1997245177.USD","LU1997245094.SGD","LU0405327148.USD","LU2148510915.USD","LU1093756325.SGD","IE00B2B36J28.USD","LU1571399168.USD","LU2242646821.SGD","BK0060","LU2097828631.EUR","LU1983299246.USD","BK0028","BK4581","LU2328871848.SGD","LU0456855351.SGD","LU1093756168.USD","LU1989771016.USD","LU1820825898.SGD","LU2097828714.EUR","LU1655091616.SGD","LU2125154935.USD","VXUS","600276","LU0267386448.USD","LU1670711040.USD","BMY","BK0188","BK0012","LU0432979614.USD","LU1074936037.SGD","IE0002141913.USD","LU1670710588.SGD","LU2488822045.USD","LU0306807586.USD","LU1032466523.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195012050","title":"异动解读 | 与百时美施贵宝达成152亿美元重磅合作，恒瑞医药盘中大涨14.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=1195012050","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195012050?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:16","pubTimestamp":1778563004,"startTime":"0","endTime":"0","summary":"恒瑞医药今日盘中大幅上涨14.46%，股价异动明显，引发市场高度关注。消息面上，公司午间发布公告，宣布与美国制药巨头百时美施贵宝达成全球战略合作及许可协议。根据协议，双方将共同推进13款涵盖肿瘤学、血液学及免疫学的早期项目，BMS将向恒瑞支付可达9.5亿美元的相关付款，包括6亿美元首付款，协议的潜在总交易额最高可达约152亿美元。此次合作涉及恒瑞的4个肿瘤及血液病项目、BMS的4个免疫学项目以及双方共同研发的5个创新项目。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634326269","title":"恒瑞医药港股午后拉升涨逾15% 与BMS达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2634326269","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634326269?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:11","pubTimestamp":1778562660,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　恒瑞医药港股午后跳升15%，最高触及76.75港元。\n\n　　消息面上，恒瑞医药（01276.HK）公布，公司与百时美施贵宝公司（简称“BMS”）达成全球战略合作及许可协议，共同推进13款涵盖肿瘤学、血液学及免疫学的早期项目，以加速创新药物研发，惠及全球患者。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"d8fdac8d3d9097cb034fb43ab6bd5883","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-05-12/doc-inhxrfsi1348547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1997244956.HKD","LU2580892789.USD","VXUS","LU0405327494.USD","LU2495084118.USD","BK4585","LU2328871848.SGD","BK0239","LU1064130708.USD","LU1655091616.SGD","600276","LU1820825898.SGD","LU2097828631.EUR","LU2097828714.EUR","LU1781817850.SGD","LU2148510915.USD","LU0359201612.USD","LU0359201885.HKD","LU2097828805.USD","BK0183","BK4588","LU0359202008.SGD","BK0060","LU1023057109.AUD","LU1328615791.USD","BK0028","BK0012","LU1255011170.USD","LU2289578879.USD","LU1997245177.USD","LU1997245094.SGD","01276","BK1191","BMS","LU2097828474.EUR","LU2097828557.USD","LU2543165471.USD","LU2580892862.HKD","LU0405327148.USD","BK0196","BK0188","LU1146622755.USD","LU1580142542.USD","LU1064131003.USD","LU2488822045.USD","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198821818","title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=1198821818","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198821818?lang=zh_cn&edition=full","pubTime":"2026-05-12 13:03","pubTimestamp":1778562223,"startTime":"0","endTime":"0","summary":"5月12日，$恒瑞医药(01276)$午后直线拉升，一度涨超16%！该公司与BMS达成全球重磅合作，携手开发13款早期创新药。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1f4c1fa965d76d4e78087079f689b4e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"恒瑞医药与BMS达成全球重磅合作，携手开发13款早期创新药","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1781817850.SGD","BK1161","LU1969619763.USD","600276","LU1146622755.USD","BK0196","LU0359202008.SGD","LU1997244956.HKD","159992","LU0359201612.USD","LU2097828557.USD","LU1580142542.USD","LU1997245094.SGD","BMY","LU2328871848.SGD","LU0405327148.USD","LU1997245177.USD","LU2488822045.USD","LU0405327494.USD","BK0188","LU2580892862.HKD","BK0239","LU2097828474.EUR","BK0028","LU2148510915.USD","01276","LU1655091616.SGD","BK1574","BK0183","LU1328615791.USD","LU0359201885.HKD","LU1064130708.USD","LU1255011170.USD","LU1064131003.USD","LU2495084118.USD","LU1820825898.SGD","BK1191","LU2097828631.EUR","BK0012","LU2097828714.EUR","BK0060","LU1023057109.AUD","LU2580892789.USD","LU2543165471.USD","LU2097828805.USD","LU2289578879.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.1119},{"period":"1month","weight":-0.0706},{"period":"3month","weight":-0.1296},{"period":"6month","weight":-0.0944},{"period":"1year","weight":0.3961},{"period":"ytd","weight":-0.1338}],"compareEarnings":[{"period":"1week","weight":-0.0209},{"period":"1month","weight":-0.0139},{"period":"3month","weight":-0.034},{"period":"6month","weight":-0.0015},{"period":"1year","weight":0.1057},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}